Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$185.68 USD

185.68
1,137,205

+0.90 (0.49%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ionis (IONS) Q2 Loss Narrows Y/Y, Sales Surpass Estimates

by Zacks Equity Research

Ionis (IONS) Q2 loss narrows from the year-ago levels. Sales beat estimates. The company re-affirms its previously issued financial guidance for 2023.

Biotech Stock Roundup: BIIB, GSK's Q2 Earnings, KOD Faces Setback & More

by Zacks Equity Research

Earnings updates from Biogen (BIIB) and GSK (GSK) are in focus in the biotech sector.

Biogen (BIIB) Beats on Q2 Earnings & Sales, Announces Job Cuts

by Zacks Equity Research

Biogen (BIIB) beats second-quarter estimates for earnings and sales. It maintains 2023 guidance. Stock up in pre-market.

Compared to Estimates, Biogen Inc. (BIIB) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Biogen Inc. (BIIB) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Biogen Inc. (BIIB) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Biogen Inc. (BIIB) delivered earnings and revenue surprises of 6.63% and 3.32%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Biogen (BIIB) to Report Q2 Earnings: Here's What to Expect

by Zacks Equity Research

Biogen's sales in the second quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have improved.

GSK (GSK) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Biogen Inc. (BIIB) closed at $276.17, marking a -0.8% move from the previous day.

Lilly's (LLY) Donanemab Slows Alzheimer's Disease Progression

by Zacks Equity Research

Data from a phase III study shows that treatment with Eli Lilly's (LLY) donanemab slowed cognitive and functional decline by 60% in study participants at the earliest stage of Alzheimer's disease.

Earnings Preview: Biogen Inc. (BIIB) Q2 Earnings Expected to Decline

by Zacks Equity Research

Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Novartis (NVS) to Report Q2 Earnings: Is a Beat in Store?

by Zacks Equity Research

When Novartis (NVS) reports second-quarter 2023 results, investor focus is likely to be on updates related to Sandoz's spin-off besides the top- and bottom-line numbers.

Biotech Stock Roundup: BIIB, Eisai's Drug Update, NVAX Gains on Deal Amendment

by Zacks Equity Research

Regulatory and key pipeline updates from Biogen (BIIB) and Novavax (NVAX) are in focus in the biotech sector.

Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Biogen Inc. (BIIB) closed the most recent trading day at $277.41, moving -0.87% from the previous trading session.

Why Biogen Inc. (BIIB) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Should iShares Morningstar Mid-Cap Value ETF (IMCV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IMCV

Ionis (IONS) Posts Encouraging Data From Amyloidosis Drug Study

by Zacks Equity Research

Ionis (IONS) reports positive 85-week phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).

Prothena (PRTA) Alzheimer's Disease Drug Licensed by BMY

by Zacks Equity Research

Prothena (PRTA) will receive $55 million from Bristol Myers Squibb for an exclusive worldwide license to PRX005, designed for the potential treatment of Alzheimer's disease.

Biogen (BIIB) Stock Down Despite FDA Nod to Alzheimer's Drug

by Zacks Equity Research

Biogen (BIIB) stock falls despite Leqembi getting the traditional nod for the treatment of Alzheimer's Disease.

Biogen (BIIB), Eisai Get Full FDA Nod for Leqembi in Alzheimer's

by Zacks Equity Research

Following the full approval, Biogen (BIIB)/Eisai's Leqembi is the first approved treatment to slow progression of Alzheimer's disease. This also paves the way for a broader Medicare coverage.

Biotech Stock Roundup: KDNY Up on NVS Buyout, BIIB & Eisai's AD Drug Update & More

by Zacks Equity Research

Acquisition and regulatory updates from Chinook Therapeutics (KDNY) and Biogen (BIIB) are in focus in the biotech sector.

Biogen (BIIB), Eisai Alzheimer Drug Gets FDA Panel Endorsement

by Zacks Equity Research

An FDA advisory committee supports granting full approval to Biogen (BIIB)/Eisai's Alzheimer's disease antibody. NASDAQ halts BIIB's common stock trading on Jun 9.

Biogen (BIIB), Eisai's Alzheimer Drug Likely to Get Full FDA Nod

by Zacks Equity Research

Based on briefing documents issued by the FDA, a full regulatory approval is expected on Biogen (BIIB)/Eisai's Alzheimer's disease antibody. The final decision is expected in the early next month.

Biotech Stock Roundup: GSK Provides Updates, Biogen to Discontinue Study & More

by Zacks Equity Research

Regulatory and pipeline updates from GSK plc (GSK) and Biogen (BIIB) are in focus in the biotech sector.

Andrew Rocco headshot

Mastering the Double-Bottom Pattern (Unveiling 3 Intriguing Setups in Today's Market)

by Andrew Rocco

A double-bottom base is a chart pattern commonly used in technical analysis to identify a solid reward-to-risk zone in a stock. Stock Strategist Andrew Rocco walks you through the pattern and unveils 3 juicy setups.

Novo Nordisk and Golden Entertainment have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Novo Nordisk and Golden Entertainment are part of the Zacks Bull and Bear of the Day article.